ROBERT ROBY: Open Payments
NPI 1508809971 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$791 in 37 payments from 15 companies in 2025. Trend: 2023 $106 · 2024 $699 · 2025 $791
Food & beverage: $759Education: $32
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 8 | $183 |
| AstraZeneca Pharmaceuticals LP | 6 | $135 |
| Lilly USA, LLC | 6 | $108 |
| SANOFI PASTEUR INC. | 2 | $58 |
| GlaxoSmithKline, LLC. | 3 | $48 |
| ABBVIE INC. | 2 | $47 |
| Astellas Pharma US Inc | 2 | $39 |
| Eisai Inc. | 1 | $34 |
| Gilead Sciences, Inc. | 1 | $25 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $24 |
Products named: Ozempic, MOUNJARO, AIRSUPRA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, QULIPTA, Veozah, Rybelsus, FARXIGA.
Industry payments across MD — which companies pay providers there.
